Sharps Technology (NASDAQ:STSS – Get Free Report) and TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, profitability and risk.
Volatility & Risk
Sharps Technology has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for Sharps Technology and TriSalus Life Sciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sharps Technology | 0 | 0 | 0 | 0 | 0.00 |
| TriSalus Life Sciences | 0 | 0 | 6 | 2 | 3.25 |
Profitability
This table compares Sharps Technology and TriSalus Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sharps Technology | N/A | -110.40% | -73.60% |
| TriSalus Life Sciences | -206.24% | N/A | -236.83% |
Insider & Institutional Ownership
17.2% of Sharps Technology shares are held by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are held by institutional investors. 8.7% of Sharps Technology shares are held by insiders. Comparatively, 32.8% of TriSalus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Sharps Technology and TriSalus Life Sciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sharps Technology | N/A | N/A | -$9.84 million | ($8.08) | -0.25 |
| TriSalus Life Sciences | $18.51 million | 6.44 | -$59.04 million | ($2.49) | -1.57 |
Sharps Technology has higher earnings, but lower revenue than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks.
Summary
TriSalus Life Sciences beats Sharps Technology on 8 of the 14 factors compared between the two stocks.
About Sharps Technology
Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Receive News & Ratings for Sharps Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sharps Technology and related companies with MarketBeat.com's FREE daily email newsletter.
